Reshaping the Path of Vascular Cognitive Impairment (VCI)

Exclusion criteria

• . Absence of relevant small vessel ischaemic lesions on an existing brain computed tomography (CT) or MRI;
• . Diagnosed with another type of dementia (e.g., AD) or other neurological conditions (e.g., multiple sclerosis, Parkinson's disease, etc.) that affects cognition and mobility;
• . Diagnosed previously with a genetic cause of SIVCI (e.g., CADASIL);
• . At high risk for cardiac complications during exercise and/or unable to self-regulate activity or to understand recommended activity level (i.e., Class C of the American Heart Risk Stratification Criteria);
• . Participating in regular RT in the last six months;
• . Have clinically significant peripheral neuropathy or severe musculoskeletal or joint disease that impairs mobility;
• . Taking medications that may negatively affect cognitive function, such as anticholinergics, including agents with pronounced anticholinergic properties (e.g., amitriptyline), major tranquilizers (typical and atypical antipsychotics), and anticonvulsants (e.g., gabapentin, valproic acid, etc.); or
• . Individual who plans to participate or is enrolled in a clinical drug trial concurrent to this study.